Skip to main content

Table 1 Patients’ characteristics

From: Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

  Excluded from randomized controlled trial (N = 295) Included in randomized controlled trial (N = 406) P value
Demographics and background
 Age (Mean ± SD), year 65 ± 18 66 ± 17 0.411
 Gender (female) 101 (34.2%) 151 (37.2%) 0.421
 Country    0.000
  Israel 274 (92.9%) 270 (66.5%)  
  Greece 16 (5.4%) 76 (18.7%)  
  Italy 5 (1.7%) 60 (14.8%)  
 Admitted from home 204 (69.2%) 276 (68%) 0.742
 BMI, kg/m2 27.1 (6.7) 27.4 (5.8) 0.610
 Charlson Score (Mean ± SD) 2 ± 2 2 ± 2 0.497
 Dementia 17 (5.8%) 49 (10.7%) 0.050
 Diabetes 61 (20.7%) 90 (22.2%) 0.636
 Chronic kidney disease 71 (24.1%) 79 (19.5%) 0.129
 Hematological Malignancy 25 (8.5%) 14 (3.4%) 0.004
 Congestive heart failure 66 (22.4%) 92 (22.7%) 0.928
 Chronic pulmonary disease 57 (19.3%) 91 (22.4%) 0.322
 Immune suppressive therapy 54 (18.3%) 61 (15%) 0.247
 Known colonization by pathogen before infection 69 (23.4%) 96 (23.6%) 0.937
 Recent surgery 83 (28.1%) 114 (28.1%) 0.987
Status at infection onset (culture taken time)
 Temperature, °C (SD) 37.9 (1.7) 38.0 (1.7) 0.655
 Systolic blood pressure, mm Hg (SD) 106 (24) 109 (21) 0.054
 Haemodynamic support 68 (24.2%) 75 (18.5%) 0.069
 Mechanical ventilation (invasive) 198 (69.5%) 264 (65%) 0.221
 Haemodialysis 11 (3.9%) 27 (6.7%) 0.118
 SOFA score (Mean ± SD) 6 ± 3 6 ± 3 0.755
 Creatinine Clearance (Cockcroft-Gault Equation), mL/min (Percentiles 25–75) 59.79 (32.54–108.58) 69.95 (41.21–126.27) 0.012
 Albumin, g/dL (SD) 2.3 (0.6) 2.4 (0.7) 0.285
 White blood cells, thousands/mL (SD) 13.22 (9.85) 14.12 (8.89) 0.212
 Arterial line 76 (25.8%) 151 (37.2%) 0.001
 Central venous catheter 119 (40.3%) 225 (55.4%) 0.000
 Urinary catheter 228 (77.3%) 354 (87.2%) 0.001
 Nasogastric tube 201 (68.1%) 285 (70.2%) 0.559
\